In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Comparison of safety and efficacy of rule-out strategies in myocardial infarction: copeptin in combination with troponin versus 2h algorithm

Session Acute cardiac care in the emergency department

Speaker Maria Rubini Gimenez

Event : ESC Congress 2015

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Cardiac Care
  • Session type : Rapid Fire Abstracts

Authors : KS Wildi (Basel,CH), R Twerenbold (Basel,CH), M Rubini Gimenez (Basel,CH), T Reichlin (Basel,CH), M Wagener (Basel,CH), J Boeddinghaus (Basel,CH), T Nestelberger (Basel,CH), S Osswald (Basel,CH), C Mueller (Basel,CH)

Authors:
K.S. Wildi1 , R. Twerenbold1 , M. Rubini Gimenez1 , T. Reichlin1 , M. Wagener1 , J. Boeddinghaus1 , T. Nestelberger1 , S. Osswald1 , C. Mueller1 , 1University Hospital Basel - Basel - Switzerland ,

Citation:
European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 6

Purpose: Addressing the increasingly recognized, yet unmet clinical need for rapid rule-out of acute myocardial infarction (AMI), several novel strategies have been developed. Due to the lack of direct comparisons in the same dataset, selection of the best strategy for clinical practice is challenging. We therefore aimed to directly compare the safety and efficacy of two previously defined strategies (dual marker strategy with high-sensitivity cardiac troponin (hs-cTn) and copeptin at presentation versus the hs-cTn 2h-algorithm).

Methods: In a prospective international multicentre diagnostic study enrolling 1194 patients presenting with suspected AMI to the emergency department, the final diagnosis of AMI was adjudicated by two independent cardiologists using all available clinical information including serial hs-cTnT concentrations. Safety was quantified as the negative predictive value for AMI in the rule-out zone of the respective rule-out strategies. Efficacy was quantified as the percentage of the overall cohort assigned to the rule-out zone by the respective strategy. Both strategies were applied using a very well validated hs-cTn assay (hs-cTnT Roche: 99th percentile 14ng/l; 2h-algorithm 0h and 2h<14ng/l and Δ0–2h<4ng/l), the cutoff value of copeptin was determined to be 9pmol/l. As both strategies should only be applied once ST-elevation MI (STEMI) has been excluded by the initial ECG, STEMI patients were excluded from the analysis.

Results: Acute myocardial infarction was the final diagnosis in 18% of patients. The safety was very high and comparable with both algorithms (dual marker strategy: NPV 97.2%, 95% CI 95.6–98.4% versus 2h-algorithm: NPV 99.9%, 95% CI 99.3–100%, p<0.001). Regarding efficacy, copeptin in combination with hs-cTnT allowed rule-out in 48.6% of patients versus 62.1% with the 2h-algorithm (p<0.001).

Conclusion: Both investigated rule-out strategies allow a safe rule-out of AMI, but the 2h-algorithm clearly performed better. While the dual marker strategy has the obvious advantage of allowing rule-out already with the measurement at presentation, the 2h-algorithm is more effective and increases the number of patients eligible for rule-out.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are